MNX1-AS1, a c-Myc induced lncRNA, promotes the Warburg effect by regulating PKM2 nuclear translocation
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA878853 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR21508952_1.fastq.gz | Fastqsanger.gz | |||
| SRR21508952_2.fastq.gz | Fastqsanger.gz | |||
| SRR21508953_1.fastq.gz | Fastqsanger.gz | |||
| SRR21508953_2.fastq.gz | Fastqsanger.gz | |||
| SRR21508954_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 12 |
Similar Datasets
Project description:Altered glycolysis is the most fundamental metabolic change associated with the Warburg effect. However, the precise mechanisms are not completely understood. Here we dissect how MNX1-AS1 reinforces the Warburg effect through facilitating the non-glycolytic actions of PKM2 in the nucleus. We found that MNX1-AS1 expression was frequently overexpressed in hepatocellular carcinoma (HCC). In the context of HCC, we show MNX1-AS1 acts as a scaffold to promote interactions between PKM2 and importin α5. Upon EGFR activation, the resulting ternary complex drives the translocation of PKM2 into the nucleus. In consequence, glycolytic pathway components including key mediators of the Warburg effect (LDHA, Glut1 and PDK1) are upregulated. Manipulating MNX1-AS1 elicited robust effects on glycolysis associated with marked changes in HCC growth in vitro and in vivo, indicative of the significant contribution of MNX1-AS1 to tumorigenesis. Moreover, while MNX1-AS1 expression is driven by c-Myc, its actions associated with PKM2 were shown to be downstream and independent of c-Myc. Given the status of MNX1-AS1 as a pan-cancer upregulated lncRNA, this implicitly highlights the potential of targeting MNX1-AS1 to selectively counter the Warburg effect in a range of tumor types.
2022-11-23 | GSE213064 | GEO
Project description:BackgroundAltered glycolysis is the most fundamental metabolic change associated with the Warburg effect. Some glycolytic enzymes such as PKM2, the dominant pyruvate kinase in cancer cells, have been shown to engage in non-glycolytic functions that contribute to tumor metabolism. However, the precise mechanisms are not completely understood.MethodsThe role of MNX1-AS1 in hepatocellular carcinoma progression was assessed both in vitro and in vivo. Northern blotting, RNA pulldown, mass spectrometry, RNA-binding protein immunoprecipitation, ChIP, luciferase reporter assays, RNA FISH and immunofluorescence staining were used to explore the detail molecular mechanism of MNX1-AS1 in hepatocellular carcinoma (HCC).ResultsHere we dissect how MNX1-AS1, a long non-coding RNA (lncRNA), reinforces the Warburg effect through facilitating the non-glycolytic actions of PKM2 in the cell nucleus. We found that MNX1-AS1 expression was frequently overexpressed in HCC-derived cell lines and tissues compared to their normal hepatic cell counterparts, a finding consistent with its status as pan-cancer expressed lncRNA. In the context of HCC, we show MNX1-AS1 acts as a scaffold to promote interactions between PKM2 and importin α5. In response to EGFR activation, the resulting ternary complex drives the translocation of PKM2 into the nucleus. In consequence, glycolytic pathway components including key mediators of the Warburg effect (LDHA, GLUT1 and PDK1) are upregulated though the coactivator function of PKM2. Manipulating MNX1-AS1 elicited robust effects on glycolysis associated with marked changes in HCC growth in vitro and in xenograft models, indicative of the significant contribution of MNX1-AS1 to tumorigenic phenotypes. Moreover, while MNX1-AS1 expression is driven by c-Myc, its actions associated with PKM2 were shown to be downstream and independent of c-Myc.ConclusionsGiven the status of MNX1-AS1 as a pan-cancer upregulated lncRNA, this implicitly highlights the potential of targeting MNX1-AS1 to selectively counter the Warburg effect in a range of tumor types.
| S-EPMC9727912 | biostudies-literature
Project description:Pyruvate kinase M2 (PKM2) plays an important role in the consumption of glucose and the production of lactic acid, the striking feature of cancer metabolism. The association of PKM2 with osteosarcoma (OS) has been reported but its role in OS has not. To study this, we obtained PKM2-bound RNAs in HeLa cells. Peak calling analysis revealed that PKM2 binds to long noncoding RNAs (lncRNAs), which are associated with cancer pathogenesis and development. Validation of the PKM2-lncRNA interaction in the human OS cell line showed that lncRNA colon cancer associated transcript-1 (lncRNACCAT1) interacts with PKM2, which upregulates the phosphorylation of sterol regulatory element-binding protein 2. These factors promote the Warburg effect, lipogenesis, and OS cell growth. PKM2 seems to be a key regulator in OS by binding to lncCCAT1. This further extends the biological functions of PKM2 in tumorigenesis and makes it a novel potential therapeutic for OS.
2022-03-23 | GSE184327 | GEO
Project description:The leukemic cell line GDM-1 was established from a patient with acute myelomonoblastic leukemia [4]. GDM-1 cells carry a reciprocal translocation t(6;7)(q23;q36) juxtaposing the transcription factor (TF) gene motor neuron and pancreas homeobox 1 (MNX1, also designated HLXB9 or HB9) on chromosome 7 (chr7) to the locus of the transcriptional activator MYB on chr6. The translocation does not result in a fusion transcript but leads to aberrant activation of MNX1, suspected to be due to altered topologically associating domains, nuclear positioning or ectopic mechanisms. GDM-1 represents the only AML cell line overexpressing MNX1. Here we demonstrate that the interaction between the MNX1 promoter with a ‘hijacked’ enhancer from the MYB/AHI1 locus leads to ectopic activation of MNX1.
2023-02-28 | GSE221751 | GEO
Project description:The leukemic cell line GDM-1 was established from a patient with acute myelomonoblastic leukemia [4]. GDM-1 cells carry a reciprocal translocation t(6;7)(q23;q36) juxtaposing the transcription factor (TF) gene motor neuron and pancreas homeobox 1 (MNX1, also designated HLXB9 or HB9) on chromosome 7 (chr7) to the locus of the transcriptional activator MYB on chr6. The translocation does not result in a fusion transcript but leads to aberrant activation of MNX1, suspected to be due to altered topologically associating domains, nuclear positioning or ectopic mechanisms. GDM-1 represents the only AML cell line overexpressing MNX1. Here we demonstrate that the interaction between the MNX1 promoter with a ‘hijacked’ enhancer from the MYB/AHI1 locus leads to ectopic activation of MNX1.
2023-02-28 | GSE221752 | GEO
Project description:The leukemic cell line GDM-1 was established from a patient with acute myelomonoblastic leukemia [4]. GDM-1 cells carry a reciprocal translocation t(6;7)(q23;q36) juxtaposing the transcription factor (TF) gene motor neuron and pancreas homeobox 1 (MNX1, also designated HLXB9 or HB9) on chromosome 7 (chr7) to the locus of the transcriptional activator MYB on chr6. The translocation does not result in a fusion transcript but leads to aberrant activation of MNX1, suspected to be due to altered topologically associating domains, nuclear positioning or ectopic mechanisms. GDM-1 represents the only AML cell line overexpressing MNX1. Here we demonstrate that the interaction between the MNX1 promoter with a ‘hijacked’ enhancer from the MYB/AHI1 locus leads to ectopic activation of MNX1.
2023-02-28 | GSE221749 | GEO
Project description:The leukemic cell line GDM-1 was established from a patient with acute myelomonoblastic leukemia [4]. GDM-1 cells carry a reciprocal translocation t(6;7)(q23;q36) juxtaposing the transcription factor (TF) gene motor neuron and pancreas homeobox 1 (MNX1, also designated HLXB9 or HB9) on chromosome 7 (chr7) to the locus of the transcriptional activator MYB on chr6. The translocation does not result in a fusion transcript but leads to aberrant activation of MNX1, suspected to be due to altered topologically associating domains, nuclear positioning or ectopic mechanisms. GDM-1 represents the only AML cell line overexpressing MNX1. Here we demonstrate that the interaction between the MNX1 promoter with a ‘hijacked’ enhancer from the MYB/AHI1 locus leads to ectopic activation of MNX1.
2023-02-28 | GSE221748 | GEO
Project description:The leukemic cell line GDM-1 was established from a patient with acute myelomonoblastic leukemia [4]. GDM-1 cells carry a reciprocal translocation t(6;7)(q23;q36) juxtaposing the transcription factor (TF) gene motor neuron and pancreas homeobox 1 (MNX1, also designated HLXB9 or HB9) on chromosome 7 (chr7) to the locus of the transcriptional activator MYB on chr6. The translocation does not result in a fusion transcript but leads to aberrant activation of MNX1, suspected to be due to altered topologically associating domains, nuclear positioning or ectopic mechanisms. GDM-1 represents the only AML cell line overexpressing MNX1. Here we demonstrate that the interaction between the MNX1 promoter with a ‘hijacked’ enhancer from the MYB/AHI1 locus leads to ectopic activation of MNX1.
2023-02-28 | GSE221750 | GEO
Project description:Reactive astrocytes play critical roles in the occurrence of various neurological diseases such as multiple sclerosis. Activation of astrocytes is often accompanied by a glycolysis-dominant metabolic switch. We found that PKM2 displayed nuclear translocation in astrocytes of EAE mice, an animal model of multiple sclerosis. And we identified the ubiquitination-mediated regulation of PKM2 nuclear import by ubiquitin ligase TRIM21. To detect the expression of TRM21 in EAE mice, We used single-cell sequencing to analyze the expression of TRM21 in EAE mice.
2024-09-12 | GSE263883 | GEO
Project description:Acute myeloid leukemia (AML) in children with cytogenetic aberrations like translocation t(7;12)(q36;p13) is associated with inferior outcome. The translocation can lead to a fusion transcript MNX1::ETV6 but also to activation of MNX1 transcription. We generated an AML mouse model by transplantation of fetal liver cells with ectopic expression of MNX1. AML was highly penetrant in immunocompromised and less penetrant in immunocompetent mice. Transforming capacity was restricted to fetal liver cells and could not achieved with adult bone marrow cells, in concordance with the clinical finding that t(7;12)(q36;p13) is mostly restricted to infants. Ectopic expression of MNX1 led to increased H3K4methylation and reduced H3K27me3, possibly through its interaction with methyl transferases. MNX1 expression was accompanied with changes in genome wide chromatin accessibility , increased DNA damage, depletion in the LSK population and skewing toward the myeloid lineage. These effects, together with leukemia development, could be prevented by the S-adenosylmethionine analogue Sinefungin that acts as a SAM competitor and a pan methyltranferases inhibitor. Expression profiles of a human iPSC AML model with t(7;12) and of TARGET pediatric AML and TCGA patients support the rationale for targeting MNX1 and downstream pathways.
2024-09-30 | PXD034416 | Pride